• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, April 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Targets and patented drugs for chemotherapy of Chagas disease

Bioengineer by Bioengineer
January 17, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Chagas diseaseis a parasitic infection typically spread by triatomine vectors, affecting millions of people all over Latin America. Existing chemotherapy is centered on benznidazole and nifurtimox, providing unsatisfactory results and substantial side effects. The transmission of the disease by people migration has determined the emergence as a public health problem elsewhere in non-endemic countries of the word.So, the finding of novel ways to challenge this neglected disease is a main priority. Progress in scientific knowledge about Trypanosoma cruzi in the period comprising last 15-years has increased the identification of multiple targets for Chagas“ disease chemotherapy. Ergosterol biosynthesis pathway and cruzipain, the key cysteine protease (CP) of T.cruzi, considered as the best encouraging targets for trypanocidal drugs. Recent unfortunate clinical trials investigating the administration of pozoconazole and ravuconazole to chronic patients; an approach for the fast development of novel anti-T.cruzi chemotherapy focused on the CP inhibitor K777, which is close to entering the clinical trial phase. The combination of known drugs with existing trypanocidal agents and compounds recently identified as clinical candidates for Chagas disease can be considered among the finest points of the manuscript. In addition, trypanothione biosynthesis, thiol-dependant redox and polyamine metabolism, the glycolytic, glyconeogenic, pentose phosphate, lipidic and polyisoprenoid biosynthetic pathways, and specific enzymes from these biosynthetic pathways have been also specifically discussed. Novel synthesized anti-T. cruzi compounds with or without specific single or multi-target assigned have been also described in detail. In summary, loans on anti-Chagas disease agents focused to specific parasite targets as their metabolic pathways or specific enzymes have been summarized. Patent literature collected and published from 2000 to 2015, alleging inhibitors for specific T. cruzi targets or trypanocidal activity was achieved over the search database from Delphion Research intellectual property network including international patents and the European patent office, Espacenet.

###

For more information about the article, please visit https://benthamscience.com/journals/recent-patents-on-anti-infective-drug-discovery/volume/11/issue/2/page/74/

Reference: Duschak, VG.; (2016). Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period. Recent Patents on Anticancer Drug Discovery, DOI: 10.2174/1574891X11666161024165304

Media Contact

Faizan ul Haq
[email protected]
@BenthamScienceP

http://benthamscience.com/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Innovative Mapping Model Enhances Efficient Allocation of Blood Resources to Patients in Need

April 16, 2026
Neuromorphic Event-Based Camera Achieves Kilohertz Vascular Imaging and Functional Brain Reconstruction in Living Subjects

Neuromorphic Event-Based Camera Achieves Kilohertz Vascular Imaging and Functional Brain Reconstruction in Living Subjects

April 16, 2026

Community Fall Prevention Exercise Proven Safe, Effective

April 16, 2026

Adaptive Deep Learning Framework Reduces Background Artifacts in Super-Resolution Microscopy

April 16, 2026
Please login to join discussion

POPULAR NEWS

  • Scientists Investigate Possible Connection Between COVID-19 and Increased Lung Cancer Risk

    61 shares
    Share 24 Tweet 15
  • Boosting Breast Cancer Risk Prediction with Genetics

    47 shares
    Share 19 Tweet 12
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    45 shares
    Share 18 Tweet 11
  • NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    97 shares
    Share 39 Tweet 24

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Innovative Mapping Model Enhances Efficient Allocation of Blood Resources to Patients in Need

Neuromorphic Event-Based Camera Achieves Kilohertz Vascular Imaging and Functional Brain Reconstruction in Living Subjects

Community Fall Prevention Exercise Proven Safe, Effective

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 79 other subscribers
  • Contact Us

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.